Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
2011年8月4日 更新者:Novartis Pharmaceuticals
Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of Hepatitis B infection.
The results for patients taking LdT will be compared to results for patients taking lamivudine.
研究概览
详细说明
Multicenter, multinational, randomized, double-blind study designed to compare the safety and efficacy of telbivudine (600 mg/day) versus lamivudine (100 mg/day) for 104 weeks in adults with decompensated chronic hepatitis B and evidence of cirrhosis.
Patients were pre-stratified by screening Child-Turcotte-Pugh score (CTP score < 9 or ≥ 9) and ALT level (within normal limits (WNL) or > 1.0 x ULN) to help assure similar degrees of hepatic insufficiency and liver inflammation on both treatment arms.
After 104 weeks of treatment, participants were followed-up with for an additional 16 weeks.
研究类型
介入性
注册 (实际的)
232
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Hong Kong、中国
-
-
-
-
-
Tel Aviv、以色列
-
-
-
-
-
Moscow、俄罗斯联邦
- Novartis
-
-
-
-
-
Winnipeg、加拿大
-
-
-
-
-
New Delhi、印度
- Novartis
-
-
-
-
-
Taipei、台湾
-
-
-
-
-
Seoul、大韩民国
-
-
-
-
-
Hannover、德国
-
-
-
-
-
Riga、拉脱维亚
- Novartis
-
-
-
-
-
Singapore、新加坡
-
-
-
-
-
Auckland、新西兰
-
-
-
-
-
Villejuif Cedex、法国
-
-
-
-
-
Krakow、波兰
- Novartis
-
-
-
-
-
Bangkok、泰国
-
-
-
-
-
Heidelburg、澳大利亚
-
-
-
-
-
Istanbul、火鸡
- Novartis
-
-
-
-
Arizona
-
Phoenix、Arizona、美国
-
-
California
-
Los Angeles、California、美国
-
-
Colorado
-
Denver、Colorado、美国
-
-
Indiana
-
Indianapolis、Indiana、美国
-
-
Minnesota
-
Rochester、Minnesota、美国
-
-
New York
-
New York、New York、美国
-
-
Texas
-
Houston、Texas、美国
-
-
Wisconsin
-
Madison、Wisconsin、美国
-
-
-
-
-
London、英国
-
-
-
-
-
Barcelona、西班牙
-
-
-
-
-
Hanoi、越南
- Novartis
-
-
-
-
-
Kuala Lumpur、马来西亚
- Novartis
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
16年 至 70年 (孩子、成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Documented decompensated chronic hepatitis B defined by all of the following: 1. Clinical history compatible with decompensated chronic hepatitis B related cirrhosis; 2. Child-Turcotte-Pugh score > 7 points.
- Evidence of hepatic cirrhosis or portal hypertension.
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Patient is pregnant or breastfeeding.
- Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or Human immunodeficiency virus (HIV).
- Patient previously received lamivudine, adefovir, or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide analog at any time
- Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before Screening for this study.
Other protocol-defined exclusion criteria may apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Telbivudine 600 mg
Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks.
Participants were followed-up for 16 weeks post-treatment.
|
600mg/day oral tablet for 104 weeks
其他名称:
Telbivudine matching placebo or lamivudine matching placebo tablet.
|
|
有源比较器:Lamivudine 100 mg
Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks.
Participants were followed-up for 16 weeks post-treatment.
|
Telbivudine matching placebo or lamivudine matching placebo tablet.
100mg/day oral tablet for 104 weeks
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Clinical Response
大体时间:From Baseline to Week 52
|
Clinical response defined as achieving all of the following 3 criteria on at least 2 consecutive visits or at the last on-treatment visit: Serum hepatitis B virus (HBV) DNA < 4 log10 copies/mL, normal Alanine transaminase (ALT) level (ALT ≤ Upper Limit of Normal (ULN)), and improvement (a 2- point or greater reduction in Child-Turcotte-Pugh (CTP) score) or stabilization (not more than a 1-point change in CTP score), compared to the baseline value.
CTP scores range from 5-15, higher scores indicate more liver impairment.
For Improvement/Stabilization, either of the individual criteria were met.
|
From Baseline to Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Initial Clinical Response
大体时间:From Baseline to Week 104
|
Time to Clinical Response defined as the number of days elapsed from the baseline visit to achieving initial Clinical Response.
|
From Baseline to Week 104
|
|
Duration of Initial Clinical Response
大体时间:Baseline to Week 104
|
Kaplan-Meier method was used.
The duration was calculated as: date of last visit before initial loss of clinical response - date of initial clinical response occurred+1.
If a patient did not lose clinical response, it was then censored at the efficacy overall censoring date.
|
Baseline to Week 104
|
|
Number of Participants With Improvement, Stabilization, and Worsening in Child-Turcotte-Pugh (CTP) Score at Week 52 and Week 104
大体时间:From Baseline to weeks 52 and 104
|
Child-Turcotte-Pugh (CTP) uses 2 clinical variables, ascites and encephalopathy, and 3 laboratory parameters, serum bilirubin, albumin, and prothrombin time.
Each variable is assigned a score from 1 to 3, with the combined score comprising the CTP score range of 5 to 15 points.
Higher scores indicate more impaired liver function.
"Worsening" of CTP score was defined as a 2-point or greater increase from baseline, "improvement" in CTP score was defined as a 2-point or greater reduction from baseline, and "stabilization" of CTP score was defined as a change of 1-point or less from baseline.
|
From Baseline to weeks 52 and 104
|
|
Number of Participants With Improvement, Stabilization, and Worsening in a Modified (3-component) CTP Score
大体时间:Baseline and Week 104
|
Modified CTP was calculated using the 3 biochemical-components (serum bilirubin, albumin, and prothrombin).
Total scores range from 3-9; higher scores indicate more liver impairment.
Improvement was defined as 2-point or greater reduction in score from baseline.
Stabilization comprises a score change of 1-point or less from baseline.
Worsening of CTP score was defined as a 2-point or greater increase from baseline.
The rationale for assessing changes in this modified (3-component) CTP score is that this maneuver removed the two subjective components of CTP scoring (ascites and encephalopathy).
|
Baseline and Week 104
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- E.J. Gane, H.L. Chan, G. Choudhuri, D.J. Suh4, A. Chutaputti, R. Safadi, T. Tanwandee, S. Thongsawat, N. Assy, S.K. Sarin, W. Bao, A. Trylesinski, C. Avila. TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE. Journal of Hepatology 52, Supplement 1, Page S4. April 2010
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2003年12月1日
初级完成 (实际的)
2009年12月1日
研究注册日期
首次提交
2004年1月20日
首先提交符合 QC 标准的
2004年1月21日
首次发布 (估计)
2004年1月22日
研究记录更新
最后更新发布 (估计)
2011年9月5日
上次提交的符合 QC 标准的更新
2011年8月4日
最后验证
2011年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.